NCT04523922View on ClinicalTrials.gov

Oxytocin to Enhance Integrated Treatment for AUD and PTSD

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

180

Participants

Timeline

Start Date

March 29, 2021

Primary Completion Date

January 1, 2026

Study Completion Date

January 1, 2026

Conditions
PTSDAlcohol Use Disorder
Interventions
DRUG

40 IU Intranasal Oxytocin

40 IU Intranasal Oxytocin self administered 30 minutes prior to each COPE session.

DRUG

Placebo

Placebo (intranasal saline spray) self administered 30 minutes prior to each COPE session.

BEHAVIORAL

Concurrent Treatment of PTSD and Substance Use Disorders using Prolonged Exposure

12 weekly sessions of COPE therapy for PTSD and AUD.

Trial Locations (1)

29401

Medical University of South Carolina, Charleston

All Listed Sponsors
collaborator

National Institute on Alcohol Abuse and Alcoholism (NIAAA)

NIH

lead

Medical University of South Carolina

OTHER